Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hypertension
Volume 2013, Article ID 541689, 9 pages
http://dx.doi.org/10.1155/2013/541689
Clinical Study

Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study

1Clinical Cardiology Institute A.L. Myasnikov FSI Russian Cardiology Scientific and Production Complex Ministry of Health, 3rd Cherepkovskaya No. 15, Moscow 121552, Russia
2Neurovascular Hypertension and Kidney Disease Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, VIC 8008, Australia

Received 19 November 2012; Accepted 12 January 2013

Academic Editor: Eduardo Vera Tibiriçá

Copyright © 2013 Irina Chazova and Markus P. Schlaich. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Mottillo, K. B. Filion, J. Genest et al., “The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis,” Journal of the American College of Cardiology, vol. 56, pp. 1113–1132, 2010. View at Google Scholar
  2. J. W. Lin, J. L. Caffrey, M. H. Chang, and Y. S. Lin, “Sex, menopause, metabolic syndrome, and all-cause and cause-specific mortality—cohort analysis from the third national health and nutrition examination survey,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 9, pp. 4258–4267, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. I. Janssen, L. H. Powell, S. Crawford, B. Lasley, and K. Sutton-Tyrrell, “Menopause and the metabolic syndrome: the study of women's health across the nation,” Archives of Internal Medicine, vol. 168, no. 14, pp. 1568–1575, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. G. B. Phillips, T. Jing, and S. B. Heymsfield, “Does insulin resistance, visceral adiposity, or a sex hormone alteration underlie the metabolic syndrome? Studies in women,” Metabolism, vol. 57, no. 6, pp. 838–844, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. V. Regitz-Zagrosek, E. Lehmkuhl, and M. O. Weickert, “Gender differences in the metabolic syndrome and their role for cardiovascular disease,” Clinical Research in Cardiology, vol. 95, no. 3, pp. 136–147, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Rossi, A. Nuzzo, G. Origliani, and M. G. Modena, “Metabolic syndrome affects cardiovascular risk profile and response to treatment in hypertensive postmenopausal women,” Hypertension, vol. 52, no. 5, pp. 865–875, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. E. Lambert, C. I. Sari, T. Dawood et al., “Sympathetic nervous system activity is associated with obesity-induced subclinical organ damage in young adults,” Hypertension, vol. 56, no. 3, pp. 351–358, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. G. W. Lambert, N. E. Straznicky, E. A. Lambert, J. B. Dixon, and M. P. Schlaich, “Sympathetic nervous activation in obesity and the metabolic syndrome—causes, consequences and therapeutic implications,” Pharmacology and Therapeutics, vol. 126, no. 2, pp. 159–172, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. C. M. M. Licht, S. A. Vreeburg, A. K. B. Van Reedt Dortland et al., “Increased sympathetic and decreased parasympathetic activity rather than changes in hypothalamic-pituitary-adrenal axis activity is associated with metabolic abnormalities,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 5, pp. 2458–2466, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. E. Szczepanska-Sadowska, A. Cudnoch-Jedrzejewska, M. Ufnal, and T. Zera, “Brain and cardiovascular diseases: common neurogenic background of cardiovascular, metabolic and inflammatory diseases,” Journal of Physiology and Pharmacology, vol. 61, pp. 509–521, 2010. View at Google Scholar
  11. G. Mancia, P. Bousquet, J. L. Elghozi et al., “The sympathetic nervous system and the metabolic syndrome,” Journal of Hypertension, vol. 25, no. 5, pp. 909–920, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Masuo, H. Rakugi, T. Ogihara, M. D. Esler, and G. W. Lambert, “Cardiovascular and renal complications of type 2 diabetes in obesity: role of sympathetic nerve activity and insulin resistance,” Current Diabetes Reviews, vol. 6, no. 2, pp. 58–67, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. P. A. Van Zwieten, “Centrally acting antihypertensives: a renaissance of interest. Mechanisms and haemodynamics,” Journal of Hypertension, vol. 15, no. 1, pp. S3–S8, 1997. View at Google Scholar · View at Scopus
  14. M. K. Pöyhönen-Alho, K. Manhem, P. Katzman et al., “Central sympatholytic therapy has anti-inflammatory properties in hypertensive postmenopausal women,” Journal of Hypertension, vol. 26, no. 12, pp. 2445–2449, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. E. Topal, A. S. Cikim, K. Cikim, I. Temel, and R. Ozdemir, “The effect of moxonidine on endothelial dysfunction in metabolic syndrome,” American Journal of Cardiovascular Drugs, vol. 6, no. 5, pp. 343–348, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. I. Chazova, V. A. Almazov, and E. Shlyakhto, “Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin,” Diabetes, Obesity and Metabolism, vol. 8, no. 4, pp. 456–465, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Ebinç, Z. N. Ozkurt, F. A. Ebinç, D. Ucardag, O. Caglayan, and M. Yilmaz, “Effects of sympatholytic therapy with moxonidine on serum adiponectin levels in hypertensive women,” Journal of International Medical Research, vol. 36, no. 1, pp. 80–87, 2008. View at Google Scholar · View at Scopus
  18. R. Kaaja, S. Kujala, K. Manhem et al., “Effects of sympatholytic therapy on insulin sensitivity indices in hypertensive postmenopausal women,” International Journal of Clinical Pharmacology and Therapeutics, vol. 45, no. 7, pp. 394–401, 2007. View at Google Scholar · View at Scopus
  19. A. F. Sanjuliani, V. G. De Abreu, and E. A. Francischetti, “Selective imidazoline agonist moxonidine in obese hypertensive patients,” International Journal of Clinical Practice, vol. 60, no. 5, pp. 621–629, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Derosa, A. F. G. Cicero, A. D'Angelo et al., “Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial,” Clinical Therapeutics, vol. 29, no. 4, pp. 602–610, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. A. M. Sharma, T. Wagner, and P. Marsalek, “Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study,” Journal of Human Hypertension, vol. 18, no. 9, pp. 669–675, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. B. N. C. Prichard, R. Simmons, M. J. Rooks, D. A. Haworth, D. Laws, and S. Wonnacott, “A double-blind comparison of moxonidine and atenolol in the management of patients with mild-to-moderate hypertension,” Journal of Cardiovascular Pharmacology, vol. 20, no. 4, supplement, pp. S45–S49, 1992. View at Google Scholar · View at Scopus
  23. R. Wolf, “the treatment of hypertensive patients with a calcium antagonist or moxonidine: a comparison,” Journal of Cardiovascular Pharmacology, vol. 20, no. 4, supplement, pp. S42–S44, 1992. View at Google Scholar
  24. G. Trieb, B. Jäger, P. R. Hughes, and P. Gardosch von Krosigk, “Long-term evaluation of the antihypertensive efficacy and tolerability of the orally-acting imidazoline I1 receptor agonist moxonidine,” European Journal of Clinical Research, vol. 7, pp. 227–240, 1995. View at Google Scholar
  25. M. Frei, L. Kuster, P. P. G. Von Krosigk, H. F. Koch, and H. Kuppers, “Moxonidine and hydrochlorothiazide in combination: a synergistic antihypertensive effect,” Journal of Cardiovascular Pharmacology, vol. 24, no. 1, supplement, pp. S25–S28, 1994. View at Google Scholar · View at Scopus
  26. S. E. Kjeldsen, L. Naditch-Brule, S. Perlini, W. Zidek, and C. Farsang, “Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the Global Cardiometabolic Risk Profile in Patients with hypertension disease survey,” Journal of Hypertension, vol. 26, no. 10, pp. 2064–2070, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. R. E. Schmieder, K. F. Hilgers, M. P. Schlaich, and B. M. Schmidt, “Renin-angiotensin system and cardiovascular risk,” Lancet, vol. 369, no. 9568, pp. 1208–1219, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. W. P. T. James, I. D. Caterson, W. Coutinho et al., “Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects,” New England Journal of Medicine, vol. 363, no. 10, pp. 905–917, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. W. Zidek, L. Naditch-Brûlé, S. Perlini, C. Farsang, and S. E. Kjeldsen, “Blood pressure control and components of the metabolic syndrome: the GOOD survey,” Cardiovascular Diabetology, vol. 8, article 51, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. F. Mahfoud, M. Schlaich, I. Kindermann et al., “Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study,” Circulation, vol. 123, pp. 1940–1946, 2011. View at Google Scholar
  31. P. Palatini, “Elevated heart rate in cardiovascular diseases: a target for treatment?” Progress in Cardiovascular Diseases, vol. 52, pp. 46–60, 2009. View at Google Scholar
  32. K. Fox, J. S. Borer, A. J. Camm et al., “Resting heart rate in cardiovascular disease,” Journal of the American College of Cardiology, vol. 50, no. 9, pp. 823–830, 2007. View at Publisher · View at Google Scholar · View at Scopus